Dr. Isaiah J Day

Dr. Isaiah J Day

Dr. Isaiah J Day

Principal Investigator

Dermatology

Dr. Isaiah J Day is a board-certified dermatologist in Canada, the United States and the UK. After completing medical school, he entered a five-year dermatology specialty training program at the University of Alberta. Upon successful completion of his fellowship examination, Dr. Day became a member of the Royal College of Physicians and Surgeons of Canada.

Dr. Day went on to become the first Canadian to complete a minimally invasive skin cancer surgery sub-specialty training program at the prestigious St. John’s Institute of Dermatology in London, England. He has established central Alberta’s only Mohs micrographic surgery non-hospital skin cancer treatment centre. While in London Dr. Day also completed a one-year fellowship in procedural dermatology, providing breadth and experience in cosmetic, surgical and laser treatments.

Dr. Day is a Principal Investigator at CaRe Clinics, as well as a Clinical Lecturer of Medicine at the University of Alberta and the University of Calgary. He has won several accolades for research and teaching. He is actively involved in teaching physicians, medical students and pharmacists in Red Deer and throughout Alberta. He is also actively involved in medical research and research studies. Dr Day’s research areas of interest include Psoriasis, Chronic Hand Eczema, Hidradenitis Suppurativa, Palmoplantar Pustulosis, Chronic Spontaneous Urticaria, Alopecia Areata, Prurigo Nodularis, Lichen Planus, Vitiligo, and Atopic Dermatitis. 

Dr. Day and his team help patients achieve their skin care goals by listening to their needs, recommending the most effective treatment plan including effective cosmetic products, dermatologic services and clinical research as an option of care plan.

Contact Information:

Phone: +1-587-797-4443

Email: isaiah@careclinicrd.ca

Address: Suite 160, 6900 Taylor Drive, Red Deer, Alberta, Canada T4P 1K4

Dr. Day has been the Principal Investigator on the following clinical trials:

Palmoplantar Pustulosis

Adults | Phase III | 2025

Alopecia Areata

Adolescents | Phase III | 2025

Atopic Dermatitis

Adults; Adolescents | Phase III | 2025

Atopic Dermatitis

Adults | Phase II | 2025

Chronic Spontaneous Urticaria

Adults | Phase IIb | 2025

Alopecia Areata

Children | Phase III | 2025

Alopecia Areata

Adults; Adolescents | Phase III | 2025

Hidradenitis Suppurativa

Adults | Phase II | 2025

Atopic Dermatitis

Infants | Phase III | 2025

Atopic Dermatitis - Hand & Foot

Adults; Adolescents | Phase III | 2025

Atopic Dermatitis

Adults | Phase II | 2025

Psoriasis

Adults | Phase III | 2025

Atopic Dermatitis

Adults; Adolescents | Phase III | 2024

Alopecia Areata

Children | Phase III | 2024

Vitiligo

Adults; Adolescents | Phase III | 2024

Hidradenitis Suppurativa

Adults; Adolescents | Phase III | 2024

Psoriasis

Adults | Phase III | 2023

Psoriasis

Adults | Phase III | 2023

Atopic Dermatitis

Adults | Phase II/III | 2023

Vitiligo

Adults; Adolescents | Phase III | 2023

Chronic Hand Eczema

Adults | Phase III | 2023

Atopic Dermatitis & Chronic Hand Eczema

Adults; Adolescents | Phase IIb | 2023

Chronic Hand Eczema

Adults | Phase II | 2023

Psoriasis

Adults | Phase III | 2023

Atopic Dermatitis

Adults | Phase II | 2022

Chronic Spontaneous Urticaria

Adults | Phase II | 2022

Chronic Hand Eczema

Adolescents | Phase III | 2022

Atopic Dermatitis

Adults | Phase IV | 2022

Alopecia Areata

Adults | Phase III | 2022

Plaque Psoriasis

Adults | Phase IIb | 2021

Chronic Hand Eczema

Adults | Phase III | 2021

Chronic Hand Eczema

Adults | Phase III | 2021

Prurigo Nodularis

Adults | Phase IIa/b | 2021

Prurigo Nodularis

Adults | Phase IIa/b | 2021

Psoriasis

Adults | Phase IV | 2021

Atopic Dermatitis

Adults | Phase III | 2021

Alopecia Areata

Adults | Phase III | 2021

Psoriasis

Children; Adolescents | Phase III | 2020

Atopic Dermatitis

Adults | Phase IIb | 2020

Atopic Dermatitis

Adults | Phase IIb | 2020

Atopic Dermatitis

Adults | Phase III | 2020

Atopic Dermatitis

Adults | Phase III | 2020

Atopic Dermatitis

Adolescents | Phase III | 2020

Psoriasis

Adults | Phase IV | 2020

Palmoplantar Pustulosis (PPP)

Adults | Phase IIb | 2019

Atopic Dermatitis

Adults; Adolescents; Children | Phase I | 2018

Palmoplantar Pustulosis

Adults | Phase II | 2018

Plaque Psoriasis

Adults; Adolescents | Phase III | 2017

See Dr. Day's research experience by indication:

Adolescents | Phase III | 2025
Children | Phase III | 2025
Adults; Adolescents | Phase III | 2025
Children | Phase III | 2024
Adults | Phase III | 2022
Adults | Phase III | 2021
Adults; Adolescents | Phase III | 2025
Adults | Phase II | 2025
Infants | Phase III | 2025
Adults | Phase II | 2025
Adults; Adolescents | Phase III | 2024
Adults | Phase II | 2022
Adults | Phase IV | 2022
Adults | Phase III | 2021
Adults | Phase IIb | 2020
Adults | Phase IIb | 2020
Adults | Phase III | 2020
Adults | Phase III | 2020
Adolescents | Phase III | 2020
Adults; Adolescents; Children | Phase I | 2018
Adults; Adolescents | Phase IIb | 2023
Adults; Adolescents | Phase III | 2025
Adults | Phase III | 2023
Adults | Phase II | 2023
Adolescents | Phase III | 2022
Adults | Phase III | 2021
Adults | Phase III | 2021
Adults | Phase IIb | 2025
Adults | Phase II | 2022
Adults | Phase II | 2025
Adults; Adolescents | Phase III | 2024
Adults | Phase III | 2025
Adults | Phase IIb | 2019
Adults | Phase II | 2018
Adults | Phase IIb | 2021
Adults; Adolescents | Phase III | 2017
Adults | Phase III | 2025
Adults | Phase III | 2023
Adults | Phase III | 2023
Adults | Phase III | 2023
Adults | Phase IV | 2021
Children; Adolescents | Phase III | 2020
Adults | Phase IV | 2020
Adults; Adolescents | Phase III | 2024
Adults; Adolescents | Phase III | 2023

Add Your Heading Text Here